Last mentioned: Jun 18, 2026
Across the most recent 2 stories covering U.S. Food and Drug Administration (FDA) — 50% positive, 50% neutral sentiment, averaging 7.5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Comment Period Close
Expected deadline for industry stakeholders to submit feedback on the proposed framework.
Customized Drug Proposal
FDA formally proposes the new system for approving bespoke therapies for rare diseases.
SCOTUS Mifepristone Hearing
Supreme Court hears arguments regarding the FDA's regulation of medication abortion pills.
National Data Release
Reports confirm U.S. abortion numbers held steady despite 14 state-level bans.
Shield Law Expansion
States like MA and NY implement laws protecting providers from out-of-state legal actions.
FDORA Enacted
The Food and Drug Omnibus Reform Act authorizes the FDA to establish a Platform Technology Designation.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to the states.
Orphan Drug Act
Congress passes legislation providing financial incentives for rare disease research.
Despite the implementation of near-total bans in 14 states, the national volume of abortions in the U.S. has remained steady or increased. This resilience is driven by a surge in medication abortion, the expansion of telehealth, and the emergence of state 'shield laws' that protect providers across jurisdictional lines.
Source: kansaspublicradio.org · ypradio.org
The FDA has proposed a landmark regulatory system designed to accelerate the approval of customized, 'bespoke' medicines for ultra-rare diseases. The framework allows manufacturers to leverage data from established platform technologies to streamline the development of individualized genomic treatments.
Source: journalgazette.net · wyff4.com
This page surfaces every story mentioning U.S. Food and Drug Administration (FDA) across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where U.S. Food and Drug Administration (FDA) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |